RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Voluntary licensing agreements cover 129 countries in regions which account for the substantial majority of new HIV diagnoses globally.
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
